

MICROWAVE SYNTHESIS OF LANSOPRAZOLE DRUG INTERMEDIATE

B. Sailu, K.Ramakrishna, A.Komaraiah and P.S.N.Reddy*

Department of Chemistry, Osmania University, Hyderabad -500007, INDIA

Tel: +91-40- 27682337; e-mail: psnreddy@yahoo.com

Abstract: The sulfide intermediate, ('2-[[[3-Methyl-4- (2,2,2-trifluoroethoxy)-2-pyridinyl] methyl] thio]-1H-benzimidazole) (3), required for the industrial synthesis of the anti-ulcer drug Lansoprazole, has been prepared in excellent yields by microwave irradiation of a dry mixture of 2-chloromethyl-3-methyl-4- (2,2,2-trifluoroethoxy)pyridine hydrochloride (1) and 2-mercaptobenzimidazole (2) in the presence of Na₂CO₃.


Keywords: Microwave irradiation, Lansoprazole, 2-Mercaptobenzimidazole, 2-Chloromethyl -3-methyl-4- (2,2,2-trifluoroethoxy) pyridine hydrochloride.

Introduction

Lansoprazole (4) is a proton pump inhibitor and has successfully been used to heal and relieve symptoms of duodenal ulcers and gastro-esophageal reflex.¹ Industrially, 4 has been synthesized by mCPBA oxidation² of the sulfide intermediate 3 that was obtained from 2-mercaptobenzimidazole³ (2) and 2-chloromethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine hydrochloride⁴ (1). Reaction media such as heterogeneous catalysis, p-toluenesulfonyl chloride-K₂CO₃,⁵ p-toluenesulfonyl chloride-NaHCO₃, PBr₃-Na₂S₂O₃,⁶ PPh₃,⁷ O(SO₂Me)₂-Et₃N,⁸ borohydride exchange resin,⁹ NaOH-PCl₃¹⁰ and PhCONH₂-Pd (PPh₃)₄¹¹ were used in the synthesis of 3, The procedures are tedious and pollutes the environment. Hence, the search for a simpler, high yielding and greener synthesis of 4 continues.

Results and discussions

We report here a new and efficient synthesis of the drug intermediate 3 and its derivatives. As a representative example, the synthesis of 3a is discussed. An equimolar mixture of 2-mercaptobenzimidazole (2a), 2-chloromethyl-3-methyl-4-(2,2,2-trifluoroethoxy) pyridine hydrochloride (1), and anhydrous sodium carbonate was exposed to microwave radiation in a 600 watt Microwave oven for 2 -10 minutes. The melt was chromatographed over silica gel (60-120 mesh) and eluted with benzene-ethylacetate solvent mixture. The sulfide intermediate 3 was isolated in 85 per cent yield and was characterized by comparing with an authentic sample¹ and by converting it to lansoprazole 4 by a known procedure.¹ The MW synthesis of 3 was extended to five other derivatives 2(b-f). In all cases, the corresponding sulfide intermediates 3(b-f) were isolated in 80-85 per cent yield (Table), and characterized by spectral data. This solvent-free reaction is an important example of green synthesis.



Experimental


General

Melting points in °C were determined on Polomon melting point apparatus (Model. No. M.P-96) and are uncorrected. IR Spectra were recorded on Shimadzu-435 spectrophotometer as KBr pellets, EI-MS on a VG Micromass 7070H (70 eV) instrument and ¹H-NMR Spectra were taken in DMSO-d₆ on a Varian Gemini 200 MHz Spectrometer using TMS as internal standard. Microwave irradiation was carried out in BPL-Sanyo, BMO and 700T domestic microwave oven at an out put of 600 watts

Experimental procedure

2-[[[3-Methyl-4- (2, 2, 2-trifluoroethoxy)-2-pyridinyl] methyl] thio]-1H-benzimidazole 3. An equimolar solid mixture of 2-chloromethyl-3-methyl-4-(2,2,2-trifluoroethoxy) pyridine hydrochloride (1, 1 g), 2-mercaptobenzimidazole (2, 0.697 g), and anhydrous sodium carbonate (0.445 g) was irradiated with microwave irradiation in a 600 watt Microwave oven for 2-10 minutes in a Pyrex conical flask. After the reaction time, the melt was cooled to room temperature dissolved in methanol, adsorbed on silica gel (60-120 mesh) and chromatographed over silica gel (60-120 mesh). The column was eluted with benzene-ethyl acetate solvent mixture (7:3). The sulfide intermediate 3 was isolated from the eluant fractions in 85% yield (4.25 g) and characterized by spectral data.

Table: Reaction conditions and yields of the '2-[[[3-Methyl-4- (2, 2, 2-trifluoroethoxy)-2-pyridinyl] methyl] thio]-1H-benzimidazole (3)



Entry	R	Time (min.)	Yield (%)	M.P. (°C)
3a	H	2	85	126-128
3b	Cl	2.5	80	190-192
3c	CH ₃	3	75	156-158
3d	OCH ₃	8	60	152-154
3e	OH	6	65	110-112
3f	NO ₂	10	56	220-222

IR, PMR and Mass data of 3(a-f) & 4

3a: IR (KBr) 3553, 3053, 1893, 1658, 1577, 1444, 1409, 1284, 1254, 1162, 1109, 976, 857, 745, 664, 576; ¹H NMR (200 MHz, CDCl₃): δ 8.40 (1H, d, *J* = 5.7 Hz), 7.53 (2H, dd, *J* = 6.0, 3.2 Hz), 7.18 (2H, dd, *J* = 6.0, 3.2 Hz), 6.72 (1H, d, *J* = 5.7 Hz), 4.41 (2H, q, *J* = 7.7 Hz), 4.40 (2H, s), 2.31 (3H, s); ESIMS: *m/z* 354 (*M*⁺) (100%).

3b: IR (KBr) 3050, 2951, 2870, 1654, 1582, 1452, 1415, 1332, 1271, 1162, 1115, 972, 918, 864, 791, 664, 577; ¹H NMR (200 MHz, CDCl₃): δ 8.40 (1H, d, *J* = 5.7 Hz), 7.49 (2H, dd, *J* = 6.0, 3.2 Hz), 7.18 (1H, d, *J* = 6.0, 3.2 Hz), 6.72 (1H, d, *J* = 5.7 Hz), 4.7 (2H, s), 4.51 (2H, q, *J* = 7.7 Hz), 2.31 (3H, s); ESIMS: *m/z* 388 (*M*⁺) (100%).

3c: IR (KBr) 2942, 1654, 1585, 1478, 1454, 1272, 1169, 1111, 1037, 975, 914, 839, 809, 756, 665, 579, 543; ¹H NMR (200 MHz, CDCl₃): δ 8.40 (1H, d, *J* = 5.7 Hz), 7.49 (2H, dd, *J* = 6.0, 3.2 Hz), 7.0 (1H, d, *J* = 6.0, 3.2 Hz), 6.72 (1H, d, *J* = 5.7 Hz), 4.7 (2H, s), 4.5 (2H, q, *J* = 7.7 Hz), 2.4 (3H, s), 2.31 (3H, s); ESIMS: *m/z* 368 (*M*⁺) (100%).

3d: IR (KBr) 3154, 2951, 1624, 1582, 1495, 1425, 1341, 1284, 1255, 1156, 1112, 1030, 971, 833, 794, 665, 577; ¹H NMR (200 MHz, CDCl₃): δ 8.40 (1H, d, *J* = 5.7 Hz), 7.49 (2H, dd, *J* = 6.0, 3.2 Hz), 7.0 (1H, d, *J* = 6.0, 3.2 Hz), 6.72 (1H, d, *J* = 5.7 Hz), 4.7 (2H, s), 4.5 (2H, q, *J* = 7.7 Hz), 3.85 (3H, s), 2.31 (3H, s); ESIMS: *m/z* 384 (*M*⁺) (100%).

3e: IR (KBr) 2915, 2357, 1651, 1633, 1613, 1485, 1392, 1325, 1161, 975, 810, 658, 537, 496; ¹H NMR (200 MHz, CDCl₃): δ 8.40 (1H, d, *J* = 5.7 Hz), 7.49 (2H, dd, *J* = 6.0, 3.2 Hz), 7.0 (1H, d, *J* = 6.0, 3.2 Hz), 6.72 (1H, d, *J* = 5.7 Hz), 5.35 (1H, br), 4.9 (2H, s), 4.6 (2H, q, *J* = 7.7 Hz), 2.31 (3H, s); ESIMS: *m/z* 370 (*M*⁺) (100%).

3f: IR (KBr) 2530, 1628, 1578, 1537, 1414, 1343, 1254, 1179, 1112, 1063, 969, 890, 821, 731, 686, 662, 486; ¹H NMR (200 MHz, CDCl₃): δ 8.40 (1H, d, *J* = 5.7 Hz), 7.49 (2H, dd, *J* = 6.0, 3.2 Hz), 7.18 (1H, d, *J* = 6.0, 3.2 Hz), 6.72 (1H, d, *J* = 5.7 Hz), 4.7 (2H, s), 4.51 (2H, q, *J* = 7.7 Hz), 2.31 (3H, s); ESIMS: *m/z* 399 (*M*⁺) (100%).

4: IR (KBr) 3225, 2929, 1901, 1657, 1580, 1455, 1401, 1283, 1172, 1038, 971, 857, 813, 749, 657, 527; ¹H NMR (200 MHz, CDCl₃): δ 8.34 (1H, d, *J* = 5.6 Hz), 7.65 (2H, br), 7.35 (1H, d, *J* = 3.9 Hz), 7.30 (1H, d, *J* = 3.9 Hz), 6.67 (1H, d, *J* = 5.6 Hz), 4.74 (2H, q, *J* = 13.8 Hz), 4.40 (1H, d, *J* = 7.8 Hz), 4.32 (1H, d, *J* = 7.8 Hz), 2.21 (3H, s); ESIMS: *m/z* 370 (*M*⁺) (100%).

Conclusions

Microwave heating of 2-chloromethyl-3-methyl-4-(2, 2, 2-trifluoroethoxy) pyridine hydrochloride (1) and 2-mercaptobenzimidazole (2) in the presence of Na₂CO₃ is a

simple, efficient, inexpensive and environment friendly synthesis of a valuable intermediate of Lansoprazole.

Acknowledgments

We thank the Director, IICT, and Hyderabad, India for providing NMR and Mass spectra.

References:

1. Kwang-Hyun Ahn, Hakwon Kim, Jeong Ryul Kim, Soon Chol Jeong, Tae Seop Kang, Hyun Tae Shin, and Geun Jho Lim., *Bull. Korean Chem. Soc.* **23**, 626(2002).
2. Bernhard Kohl, Ernst Sturm, Jorg Senn- Bilfinger, W. Alexander Simon, Uwe Kruger, Hartmann Schaefer, Georg Rainer, Volker Figala, and Kurt Klemm. *J. Med. Chem.* **35**, 1049(1992).
3. Juan Valdez, Roberto Cedillo, Alicia Hernandez-Campos, Lilian Yopez, Francisco Hernandez- Luis, Gabriel Navarrete – Vazquez, Amparo Tapia, Rafael Cortes, Manuel Hernandez, and Rafael Castillo, *Bioorg. Med. Chem. Lett.* **12**, 2221(2002).
4. Rane. R.A., Pathak, R. K., Kaushik. C.P, Prasad Rao K.V.V. and Kumar Ashok, *Synthe Commu.* **32(8)**, 1211(2002).
5. Kumar Ashok, Rane R. A, Kaushik. C. P, Prasad Rao. K.V.V, *Indian patent.* 182968(1999).
6. Kim Wan Joo, Kim Kyoung Soo, Kim Myung Hwa, Baek Yong Gu, Park Jong Yek, Jang Jung Min, Choi Jae Won, Yoo Yong Sang, *PCT Int. Appl.* 2002074766(2002).
7. Moon Young-Ho, Lee Kyung-Ik, Lee Gwan-Sun, *U.S.patent.* 6423846(2002).
8. Coppi Laura and Berenguer Maimo Ramon. *PCT Int. Appl.* 2001079194(2001).
9. Lim Geun-jho, Kim Dong-sung, and Yoon Nung-min, *PCT Int. Appl.* 2000027841(2000).
10. Monserrat Vidal Carlos, Serra Marcia, and Xavier, *Span.patent.* 2063705(1995).
11. Palomo Coll, and Alberto, *Span.patent.* 2036948(1995).

Received on 1st July 2006